ToolGen Q1 2026 Revenue Up 203% YoY, Operating Loss at KRW 4.59 Billion

Q1 2026 consolidated revenue KRW 3.9B (up 203% YoY from KRW 1.3B), operating loss KRW 4.59B (similar to KRW 4.69B in Q1 2025)
Net loss KRW 4.41B (vs KRW 4.44B), R&D expense KRW 1.5B (384% of revenue)
Cash & cash equivalents KRW 5.7B, debt ratio 7.7% (stable financial position)
Accumulated deficit KRW 170.5B, no dividend history
Patent licensing revenue accounts for 54.6% of total revenue (KRW 2.1B)
CRISPR core patents registered in 11 countries; total IP 371 (222 registered)
24 license-out agreements executed; Cross-License with GenEditBio in 2025
Ongoing patent interference with Broad Institute at USPTO (Senior Party status)
All convertible bonds fully converted, reducing debt